Schedule 13G ownership disclosure

Iovance Biotherapeutics Inc

Security class unavailable · CUSIP: 462260100

Event date: Unavailable

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
7,408,505
Percent of class
4.7000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000834237-22-008762
Form type
SC 13G/A
Filer
BlackRock Finance, Inc.
CIK
CIK 1364742
Filed
Feb 24, 2022
Reporting period
—
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub